In early 2026, sales of Hershey's Ice Breakers gum surged over 8% as a result of increased cases of halitosis linked to the use of GLP-1 weight loss drugs like Ozempic and Wegovy. CEO Kirk Tanner noted this trend during the company’s Q1 earnings call, indicating that the demand for breath-freshening products has risen significantly amid the popularity of these medications.
Additionally, Hershey reported a 17% increase in sales of its protein bars, which are marketed as functional snacks. This growth reflects a broader shift among consumers towards purpose-driven food choices, fueled by trends such as the adoption of GLP-1 medications.
Experts highlight that dehydration and reduced saliva flow caused by these drugs contribute to oral health issues. Ann Marie Defnet, an obesity medicine specialist, emphasizes the importance of hydration for patients using appetite suppressants. Furthermore, research indicates that these medications may foster an environment in the mouth that promotes bacteria linked to bad breath and cavities.